Drug intelligence / Profile preview

HS-20110 + bevacizumab + oxaliplatin + capecitabine

Development stage: Unknown
Lead developer: Hansoh Pharmaceutical Group
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

HS-20110 + bevacizumab + oxaliplatin + capecitabine is an investigational combination therapy being developed by Hansoh Pharmaceutical for the treatment of advanced colorectal cancer. The regimen consists of HS-20110, a novel antibody-drug conjugate (ADC) targeting Cadherin-17 (CDH17) conjugated to a topoisomerase inhibitor payload, combined with the VEGF inhibitor bevacizumab and the chemotherapy agents oxaliplatin and capecitabine (collectively known as CAPOX). CDH17 is a cell adhesion protein frequently overexpressed in gastrointestinal cancers. This combination is currently being evaluated in a Phase Ib/II clinical trial specifically for patients with advanced colorectal cancer who are non-MSI-H and BRAF V600E wild-type. In October 2025, Roche acquired exclusive worldwide rights (excluding Greater China) to develop and commercialize HS-20110.

Other names: HS-20110 + bevacizumab + CAPOX

Targets

VEGFA (Vascular endothelial growth factor A)CDH17 (Cadherin-17)DNATOP (DNA topoisomerases)

Beyond the preview

Go deeper on HS-20110 + bevacizumab + oxaliplatin + capecitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-20110 + bevacizumab + oxaliplatin + capecitabine.

Explore the full profile